Intelligent Bio Solutions Q1 Revenue Hits Record $1.39 Million

Intelligent Bio Solutions Inc. (Nasdaq: INBS) reported record fiscal first quarter 2027 revenue of $1.39 million for the three months ended September 30, 2026, up 25% year-over-year and 21% sequentially, the company announced on November 10, 2026. Gross profit reached $758,004 with a 54.5% gross margin, up from 46.6% a year earlier. Cartridge sales of $845,583 rose 32% year-over-year and accounted for 61% of quarterly revenue.

Context — Why the Quarter Matters for INBS

The company framed the quarter as its sixth consecutive period of year-over-year revenue growth and its third straight quarter above $1 million. The prior quarterly record was $1,145,802, set in the fourth quarter of fiscal 2026, so the new figure extends that peak by roughly $246,000.

The revenue mix is shifting toward consumables. Cartridge sales contributed 73% of the $280,038 year-over-year increase in total revenue, up from 58% of the total a year earlier. That matters because cartridges are described as the higher-margin product line, so each incremental reader placement compounds future recurring revenue.

Management tied the margin expansion to manufacturing efficiencies and that richer mix. CEO Harry Simeonidis said each reader draws on a recurring supply of higher-margin cartridges, which he described as driving most of the growth.

The catalyst for the next phase is regulatory. On September 9, 2026, the company submitted a 510(k) premarket notification to the FDA seeking clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The submission followed completion of precision, interference, usability, and method comparison studies during the quarter.

The company's current customer base sits outside the United States, spanning construction, manufacturing, transport and logistics, mining, energy and utilities, government, law enforcement, and drug treatment segments. U.S. entry remains a stated ambition, not a cleared outcome.

Data — What the Numbers Show

The headline figures are unambiguous. Revenue of $1,391,835 compares with $1,111,797 in the prior-year quarter. Cost of revenue rose to $633,831 from $593,506, leaving gross profit of $758,004 against $518,291 a year earlier, a 46% increase.

Gross margin expanded approximately 790 basis points year-over-year, from 46.6% to 54.5%. Other sales of $281,253 rose 52% year-over-year and represented 20% of quarterly revenue.

Operating expenses fell to $3,646,252 from $3,712,745, helped by the absence of a $261,780 long-lived asset impairment recorded a year earlier. Development and regulatory approval expenses, however, rose to $829,544 from $486,169, reflecting the clinical and regulatory work behind the 510(k).

Metric	Q1 FY2027	Q1 FY2026
Revenue	$1,391,835	$1,111,797
Gross profit	$758,004	$518,291
Gross margin	54.5%	46.6%
Net loss	$2,668,435	$2,994,992

The net loss narrowed to $2,668,435 from $2,994,992. Net loss per share was $0.86 versus $3.49, on weighted average shares of 3,095,306 against 854,693.

Cash and cash equivalents stood at $5,929,871 at September 30, 2026, up from $3,992,312 at June 30, 2026. Total assets were $13,621,675 against total liabilities of $6,269,147.

Analysis — What It Means for the Sector

The operating profile is a small-cap medtech scaling a razor-and-blade model: readers placed, cartridges consumed. Active customer accounts reached 516 as of September 30, 2026, with 27 added during the quarter, and the reader installed base stood at 1,978 units. Those placements are the leading indicator for future cartridge revenue.

Second-order effects run through adjacent diagnostics and workplace-testing names, where recurring consumable economics are the valuation driver rather than one-time hardware sales. A company proving cartridge mix can lift gross margin by roughly 790 basis points in a year strengthens the case for the model across the category, though INBS's absolute revenue base remains small.

The clear counter-argument is scale and cash burn. A $2.67 million quarterly net loss against $1.39 million of revenue means the company still spends more than it earns, and the balance sheet depends on continued access to capital. The 510(k) also carries binary risk: a clearance would open the U.S. market, while a rejection or delay leaves the company reliant on ex-U.S. sales.

Positioning is likely to hinge on regulatory headlines rather than quarterly print. Investors holding for the U.S. opportunity are effectively long a binary event; traders focused on the recurring-revenue story have a more gradual, consumable-driven thesis.

Outlook — What to Watch Next

Three catalysts frame the next several quarters. First, the FDA's review of the 510(k) premarket notification submitted September 9, 2026 — the company did not disclose a decision timeline. Second, cartridge and installed-base growth, which management expects to continue driving recurring revenue through fiscal 2027.

Third, cost discipline. Development and regulatory expenses rose sharply year-over-year, and the company said it will keep investing in clinical and regulatory work behind the submission while maintaining discipline elsewhere in the business.

On the quality front, the Intelligent Fingerprinting Drug Screening business was recertified to the ISO 13485:2016 standard by the British Standards Institution, which the company said supports alignment with the FDA's amended Quality Management System Regulation.

The report names no price levels, moving averages, or peer multiples, so no technical or valuation thresholds can be cited here. The operative variables remain the FDA decision and the pace of cartridge reorders.

Frequently Asked Questions

What does the FDA 510(k) submission mean for INBS investors?

It is the company's formal request for U.S. clearance of its Intelligent Fingerprinting Drug Screening System, filed September 9, 2026, for detection of the opiate codeine. The company said the submission included a method comparison study showing accuracy above 98%, sensitivity above 94%, and specificity of 100% across three U.S. clinical sites. Clearance would open the U.S. market; the company did not disclose expected review timing.

Why did INBS gross margin jump to 54.5%?

The company attributed the roughly 790 basis point year-over-year expansion to manufacturing efficiencies and a larger share of revenue from higher-margin cartridge consumables. Cartridge sales rose 32% year-over-year to $845,583 and reached 61% of total revenue, up from 58% a year earlier. As the installed base of 1,978 readers grows, recurring cartridge demand should keep influencing the mix.

How much cash does Intelligent Bio Solutions have?

Cash and cash equivalents totaled $5,929,871 at September 30, 2026, up from $3,992,312 at June 30, 2026, according to the condensed consolidated balance sheet. Total current assets were $9,045,463 against total current liabilities of $4,578,468. The company still posted a quarterly net loss of $2,668,435, so cash consumption remains a factor to monitor.

Bottom Line

Record revenue and a 54.5% gross margin show INBS scaling its cartridge model, but the FDA 510(k) decision now drives the story.